← Back to Screener
Immatics N.V. Ordinary Shares (IMTX)
Price$11.25
Favorite Metrics
Price vs S&P 500 (26W)-0.93%
Price vs S&P 500 (4W)8.96%
Market Capitalization$1.76B
P/E Ratio (Annual)79.47x
All Metrics
Book Value / Share (Quarterly)$4.25
P/TBV (Annual)2.48x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-34.63%
Cash Flow / Share (Quarterly)$-1.61
Price vs S&P 500 (YTD)2.24%
Net Profit Margin (TTM)-407.00%
EPS (TTM)$-1.89
10-Day Avg Trading Volume0.30M
EPS Excl Extra (TTM)$-1.89
Revenue Growth (5Y)9.05%
EPS (Annual)$-1.89
ROI (Annual)-39.31%
Net Profit Margin (5Y Avg)-163.79%
Cash / Share (Quarterly)$4.12
Revenue Growth QoQ (YoY)-64.87%
P/E Normalized (Annual)79.47x
ROA (Last FY)-34.93%
Revenue Growth TTM (YoY)-69.03%
EBITD / Share (TTM)$-1.63
ROE (5Y Avg)-90.19%
Operating Margin (TTM)-377.10%
Cash Flow / Share (Annual)$-1.61
P/B Ratio2.63x
P/B Ratio (Quarterly)2.47x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)19.53x
Net Interest Coverage (TTM)-11.09x
ROA (TTM)-34.32%
EV / EBITDA (TTM)25.41x
EPS Incl Extra (Annual)$-1.89
Current Ratio (Annual)11.72x
Quick Ratio (Quarterly)11.42x
3-Month Avg Trading Volume0.45M
52-Week Price Return171.78%
EV / Free Cash Flow (Annual)8.67x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.24
P/S Ratio (Annual)26.38x
Asset Turnover (Annual)0.09x
52-Week High$12.41
Operating Margin (5Y Avg)-164.18%
EPS Excl Extra (Annual)$-1.89
CapEx CAGR (5Y)-1.93%
Tangible BV CAGR (5Y)41.06%
26-Week Price Return7.82%
Quick Ratio (Annual)11.42x
13-Week Price Return13.63%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)11.72x
Enterprise Value$1,110.463
Revenue / Share Growth (5Y)-9.56%
Asset Turnover (TTM)0.08x
Book Value / Share Growth (5Y)21.07%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-411.13%
Cash / Share (Annual)$4.12
3-Month Return Std Dev55.70%
Net Income / Employee (TTM)$-1
ROE (Last FY)-40.58%
Net Interest Coverage (Annual)-3.31x
EPS Basic Excl Extra (Annual)$-1.89
P/FCF (TTM)18.24x
Receivables Turnover (TTM)8.07x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-1.89
Receivables Turnover (Annual)8.07x
ROI (TTM)-39.90%
P/S Ratio (TTM)26.37x
Pretax Margin (5Y Avg)-164.17%
Revenue / Share (Annual)$0.46
Tangible BV / Share (Annual)$4.24
Price vs S&P 500 (52W)136.68%
Year-to-Date Return6.38%
5-Day Price Return2.76%
EPS Normalized (Annual)$-1.89
ROA (5Y Avg)-19.11%
Net Profit Margin (Annual)-407.01%
Month-to-Date Return13.52%
Cash Flow / Share (TTM)$-1.25
EBITD / Share (Annual)$-1.66
Operating Margin (Annual)-377.11%
LT Debt / Equity (Annual)5.82x
ROI (5Y Avg)-67.06%
LT Debt / Equity (Quarterly)6.45x
EPS Basic Excl Extra (TTM)$-1.89
P/TBV (Quarterly)2.48x
P/B Ratio (Annual)2.47x
Pretax Margin (TTM)-411.12%
Book Value / Share (Annual)$4.25
Price vs S&P 500 (13W)10.77%
Beta1.33x
P/FCF (Annual)13.56x
Revenue / Share (TTM)$0.46
ROE (TTM)-41.31%
52-Week Low$3.94
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.35
4.35
4.35
4.35
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IMTXImmatics N.V. Ordinary Shares | 26.37x | -69.03% | — | — | $11.25 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Immatics NV is a biotechnology company developing T-cell redirecting immunotherapies for cancer treatment. The company generates revenue primarily through strategic partnerships and collaboration agreements with pharmaceutical and biotechnology firms. The United States represents its largest revenue source.